A condition with few treatment options finally has a promising lead
For the more than 17 million people worldwide living with binge eating disorder, effective pharmaceutical treatment has long been an unfulfilled promise. Now, researchers at University College London have found that GLP-1 receptor agonists — drugs originally developed for diabetes and later embraced for obesity — may also quiet the compulsive cycles of binge eating by acting on the brain's reward and impulse systems. The discovery does not yet translate to a prescription, but it opens a door that has been closed for a very long time.
- Binge eating disorder affects 17 million people globally, yet not a single medication has ever received regulatory approval to treat it — leaving patients with few options beyond behavioral therapy.
- UCL researchers found that GLP-1 drugs like semaglutide and tirzepatide reduced binge episodes, curbed loss-of-control eating, and eased emotional eating patterns in clinical trials.
- The drugs appear to work not just by suppressing appetite but by influencing brain regions tied to reward and impulse control — the very mechanisms that break down in binge eating disorder.
- Crucially, the research suggests these medications may address the disorder's core symptoms independent of weight loss, potentially helping patients regardless of their body weight.
- Before these findings reach clinical practice, dedicated trials must still confirm safety, efficacy, optimal dosing, and which patients stand to benefit most.
Researchers at University College London have identified a potential new frontier in treating binge eating disorder: the class of weight loss drugs known as GLP-1 receptor agonists. In clinical trials, medications including semaglutide and tirzepatide reduced the frequency of binge episodes, lessened the sensation of eating without control, and diminished emotional eating — symptoms that have long resisted pharmaceutical intervention.
Binge eating disorder affects more than 17 million people worldwide, yet no drug has ever been approved specifically to treat it. Patients and clinicians have depended almost entirely on behavioral and psychological therapies, leaving a significant gap for those who cannot access or do not respond to those approaches. Dr. Ilaria Costantini, who led the UCL research, described the disorder as causing serious disruption to daily life, underscoring the urgency of finding new options.
What makes these findings particularly compelling is the mechanism involved. Beyond reducing appetite and slowing digestion, GLP-1 drugs appear to act on brain regions associated with reward processing and impulse control — the same systems implicated in the loss of agency that defines binge eating. This suggests the medications may address the disorder's core symptoms directly, not merely as a side effect of weight loss, raising the possibility that they could help patients across a range of body weights.
The UCL review synthesizes evidence from multiple trials, building a case for further investigation. Still, the road from promising research to approved treatment is long. Dedicated clinical trials, regulatory review, and answers to questions about dosing and patient selection all lie ahead. For a field that has had little new to offer patients in years, however, the findings mark a meaningful and concrete step forward.
Researchers at University College London have found that weight loss medications commonly prescribed for obesity may also ease the symptoms of binge eating disorder, a condition that has long lacked effective pharmaceutical treatment. The discovery centers on a class of drugs called GLP-1 receptor agonists—medications that work by mimicking a hormone involved in appetite regulation. In clinical trials, these drugs reduced the frequency of binge episodes, diminished the sensation of eating without control, and lessened emotional eating patterns.
Binge eating disorder affects more than 17 million people worldwide, yet the treatment landscape remains sparse. Unlike many psychiatric conditions, no medications have received regulatory approval specifically for managing it. Patients and clinicians have relied primarily on behavioral therapies and psychological interventions, leaving a significant gap in care options for those who do not respond to or cannot access these approaches. Dr. Ilaria Costantini, who led the UCL research, emphasized that the disorder causes serious disruption to daily functioning, making the search for new therapeutic avenues urgent.
The medications under investigation include semaglutide, marketed as Ozempic and Wegovy, along with tirzepatide and liraglutide. These drugs work through multiple mechanisms: they reduce appetite, slow the rate at which the stomach empties food into the intestines, and appear to influence brain regions associated with reward processing and impulse control. That last mechanism may be particularly relevant to binge eating, which often involves a breakdown in the ability to regulate eating behavior despite a desire to do so.
The appeal of repurposing these drugs extends beyond their established role in weight management. While weight loss itself can be beneficial for people with binge eating disorder, the research suggests the medications address core symptoms of the condition itself—the compulsive eating episodes and the loss of agency that characterizes the disorder. This distinction matters because it opens the possibility that GLP-1 agonists could help people with binge eating disorder regardless of their weight status.
The findings represent a shift in how researchers think about appetite-regulating medications. Originally developed and approved for type 2 diabetes, then expanded to obesity treatment, these drugs are now being examined for psychiatric and behavioral applications. The UCL review synthesizes evidence from multiple trials, building a case that warrants further investigation and, potentially, clinical trials designed specifically to test these medications in binge eating populations.
Still, the path from promising research to clinical practice involves several steps. Regulatory approval would require dedicated trials demonstrating safety and efficacy in binge eating disorder specifically. Questions remain about optimal dosing, duration of treatment, and which patients might benefit most. The research does, however, provide a concrete direction for a field that has had few new options to offer patients in recent years.
Notable Quotes
Binge eating disorder is common and can be seriously disruptive to daily life, affecting more than 17 million people worldwide, with treatment options remaining limited and no approved medications currently available.— Dr. Ilaria Costantini, UCL Psychiatry
The Hearth Conversation Another angle on the story
Why does binge eating disorder have so few treatment options compared to other psychiatric conditions?
It's partly historical—the disorder wasn't formally recognized in diagnostic manuals until relatively recently, so research funding and pharmaceutical development lagged behind. Behavioral therapy became the standard, and the field didn't pursue medication development the way it did for depression or anxiety.
So these weight loss drugs weren't designed with binge eating in mind at all?
Not at all. They were developed for diabetes, then repurposed for obesity. The discovery that they might help binge eating came from observing patients who were taking them for weight loss and noticing improvements in their eating control.
If someone takes semaglutide for binge eating, are they also going to lose weight?
Likely, yes—that's built into how the drug works. But the research suggests the appetite suppression is only part of the story. These drugs seem to affect how the brain processes reward and impulse, which is central to binge eating itself.
What's the difference between using it for weight loss versus using it for the disorder?
The intent and the outcome measure. For weight loss, success is measured in pounds. For binge eating disorder, success is measured in restored control—fewer episodes, less distress, better daily functioning. A person might lose weight and still struggle with the psychological experience of binge eating.
How close are we to seeing these prescribed for binge eating?
The research is promising but preliminary. Before doctors can prescribe them specifically for this condition, there need to be dedicated clinical trials and regulatory approval. Right now, any use would be off-label—doctors using approved medications for a condition they weren't officially approved for.
What happens to the 17 million people with this disorder in the meantime?
They continue relying on therapy and behavioral strategies, which do help many people. But for those who don't respond or can't access those services, this research offers hope that options might expand in the next few years.